Symptoms of overdose: blurred vision (continuing) or changes in near vision, clumsiness or unsteadiness, confusion, convulsions, difficulty in breathing, muscle weakness (severe), or tiredness (severe), dizziness, drowsiness (severe), dryness of mouth, nose, or throat (severe), fast heartbeat, fever, hallucinations, slurred speech, unusual excitement, nervousness, restlessness, or irritability, unusual warmth, dryness, and flushing of skin.
Methantheline is a synthetic antispasmodic. Antispasmodics are used to relieve cramps or spasms of the stomach, intestines, and bladder. Methantheline is used to treat intestine or stomach ulcers (peptic ulcer disease), intestine problems (irritable bowel syndrome), pancreatitis, gastritis, biliary dyskinesia, pylorosplasm, or urinary problems (reflex neurogenic bladder in children).
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Aclidinium | The risk or severity of adverse effects can be increased when Methantheline is combined with Aclidinium. |
| Mianserin | Mianserin may increase the anticholinergic activities of Methantheline. |
| Mirabegron | The risk or severity of urinary retention can be increased when Methantheline is combined with Mirabegron. |
| Pramlintide | The risk or severity of reduced gastrointestinal motility can be increased when Pramlintide is combined with Methantheline. |
| Secretin porcine | The therapeutic efficacy of Secretin porcine can be decreased when used in combination with Methantheline. |
| Tiotropium | The risk or severity of adverse effects can be increased when Methantheline is combined with Tiotropium. |
| Topiramate | The risk or severity of hyperthermia and oligohydrosis can be increased when Methantheline is combined with Topiramate. |
| Umeclidinium | The risk or severity of adverse effects can be increased when Methantheline is combined with Umeclidinium. |
| Atazanavir | Methantheline can cause a decrease in the absorption of Atazanavir resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Cefditoren | The serum concentration of Cefditoren can be decreased when it is combined with Methantheline. |
| Dabigatran etexilate | Methantheline can cause a decrease in the absorption of Dabigatran etexilate resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Dabrafenib | Methantheline can cause a decrease in the absorption of Dabrafenib resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Erlotinib | Methantheline can cause a decrease in the absorption of Erlotinib resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Pazopanib | Methantheline can cause a decrease in the absorption of Pazopanib resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Riociguat | Methantheline can cause a decrease in the absorption of Riociguat resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Benzylpenicilloyl polylysine | Methantheline may decrease effectiveness of Benzylpenicilloyl polylysine as a diagnostic agent. |
| Betahistine | The therapeutic efficacy of Betahistine can be decreased when used in combination with Methantheline. |
| Hyaluronidase (ovine) | The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Methantheline. |
| Hyaluronidase (human recombinant) | The therapeutic efficacy of Hyaluronidase (human recombinant) can be decreased when used in combination with Methantheline. |
| Hyaluronidase | The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Methantheline. |
| Bosutinib | Methantheline can cause a decrease in the absorption of Bosutinib resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Cefpodoxime | Methantheline can cause a decrease in the absorption of Cefpodoxime resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Cefuroxime | Methantheline can cause a decrease in the absorption of Cefuroxime resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Dasatinib | Methantheline can cause a decrease in the absorption of Dasatinib resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Delavirdine | Methantheline can cause a decrease in the absorption of Delavirdine resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Dexmethylphenidate | The therapeutic efficacy of Dexmethylphenidate can be decreased when used in combination with Methantheline. |
| Amprenavir | Methantheline can cause a decrease in the absorption of Amprenavir resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Fosamprenavir | Methantheline can cause a decrease in the absorption of Fosamprenavir resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Gefitinib | Methantheline can cause a decrease in the absorption of Gefitinib resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Indinavir | Methantheline can cause a decrease in the absorption of Indinavir resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Itraconazole | Methantheline can cause a decrease in the absorption of Itraconazole resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Ledipasvir | Methantheline can cause a decrease in the absorption of Ledipasvir resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Methylphenidate | The therapeutic efficacy of Methylphenidate can be decreased when used in combination with Methantheline. |
| Nelfinavir | Methantheline can cause a decrease in the absorption of Nelfinavir resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Nilotinib | Methantheline can cause a decrease in the absorption of Nilotinib resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Rilpivirine | Methantheline can cause a decrease in the absorption of Rilpivirine resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Risedronic acid | Methantheline can cause an increase in the absorption of Risedronic acid resulting in an increased serum concentration and potentially a worsening of adverse effects. |
| Saquinavir | Methantheline can cause an increase in the absorption of Saquinavir resulting in an increased serum concentration and potentially a worsening of adverse effects. |
| Glycopyrronium | The risk or severity of adverse effects can be increased when Methantheline is combined with Glycopyrronium. |
| Levothyroxine | Methantheline can cause a decrease in the absorption of Levothyroxine resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Bisacodyl | The therapeutic efficacy of Bisacodyl can be decreased when used in combination with Methantheline. |
| Captopril | Methantheline can cause a decrease in the absorption of Captopril resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Rifampin | Methantheline can cause a decrease in the absorption of Rifampicin resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Memantine | Methantheline may decrease the excretion rate of Memantine which could result in a higher serum level. |
| Botulinum toxin type A | The risk or severity of adverse effects can be increased when Methantheline is combined with Botulinum toxin type A. |
| Glucagon | Methantheline may increase the gastrointestinal motility reducing activities of Glucagon. |
| Sulpiride | The therapeutic efficacy of Sulpiride can be increased when used in combination with Methantheline. |
| Botulinum toxin type B | The risk or severity of adverse effects can be increased when Methantheline is combined with Botulinum toxin type B. |
| Mesalazine | Methantheline can cause a decrease in the absorption of Mesalazine resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Mycophenolate mofetil | Methantheline can cause a decrease in the absorption of Mycophenolate mofetil resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Mycophenolic acid | Methantheline can cause a decrease in the absorption of Mycophenolic acid resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Tolevamer | The therapeutic efficacy of Tolevamer can be decreased when used in combination with Methantheline. |
| Eluxadoline | The risk or severity of constipation can be increased when Methantheline is combined with Eluxadoline. |
| Ramosetron | The risk or severity of constipation can be increased when Methantheline is combined with Ramosetron. |
| Amphetamine | Amphetamine may decrease the sedative activities of Methantheline. |
| Phentermine | Phentermine may decrease the sedative activities of Methantheline. |
| Pseudoephedrine | Pseudoephedrine may decrease the sedative activities of Methantheline. |
| Benzphetamine | Benzphetamine may decrease the sedative activities of Methantheline. |
| Diethylpropion | Diethylpropion may decrease the sedative activities of Methantheline. |
| Lisdexamfetamine | Lisdexamfetamine may decrease the sedative activities of Methantheline. |
| Mephentermine | Mephentermine may decrease the sedative activities of Methantheline. |
| MMDA | MMDA may decrease the sedative activities of Methantheline. |
| Midomafetamine | Midomafetamine may decrease the sedative activities of Methantheline. |
| 2,5-Dimethoxy-4-ethylamphetamine | 2,5-Dimethoxy-4-ethylamphetamine may decrease the sedative activities of Methantheline. |
| 4-Bromo-2,5-dimethoxyamphetamine | 4-Bromo-2,5-dimethoxyamphetamine may decrease the sedative activities of Methantheline. |
| Tenamfetamine | Tenamfetamine may decrease the sedative activities of Methantheline. |
| Chlorphentermine | Chlorphentermine may decrease the sedative activities of Methantheline. |
| Methylenedioxyethamphetamine | Methylenedioxyethamphetamine may decrease the sedative activities of Methantheline. |
| Dextroamphetamine | Dextroamphetamine may decrease the sedative activities of Methantheline. |
| Metamfetamine | Metamfetamine may decrease the sedative activities of Methantheline. |
| Iofetamine I-123 | Iofetamine I-123 may decrease the sedative activities of Methantheline. |
| Ritobegron | Ritobegron may decrease the sedative activities of Methantheline. |
| Mephedrone | Mephedrone may decrease the sedative activities of Methantheline. |
| Methoxyphenamine | Methoxyphenamine may decrease the sedative activities of Methantheline. |
| Gepefrine | Gepefrine may decrease the sedative activities of Methantheline. |
| 2,5-Dimethoxy-4-ethylthioamphetamine | 2,5-Dimethoxy-4-ethylthioamphetamine may decrease the sedative activities of Methantheline. |
| Phendimetrazine | Phendimetrazine may decrease the sedative activities of Methantheline. |
| Naltrexone | The risk or severity of adverse effects can be increased when Methantheline is combined with Naltrexone. |
| Bezitramide | The risk or severity of adverse effects can be increased when Methantheline is combined with Bezitramide. |
| Tramadol | The risk or severity of adverse effects can be increased when Methantheline is combined with Tramadol. |
| Morphine | The risk or severity of adverse effects can be increased when Methantheline is combined with Morphine. |
| Codeine | The risk or severity of adverse effects can be increased when Methantheline is combined with Codeine. |
| Hydromorphone | The risk or severity of adverse effects can be increased when Methantheline is combined with Hydromorphone. |
| Methadone | The risk or severity of adverse effects can be increased when Methantheline is combined with Methadone. |
| Meperidine | The risk or severity of adverse effects can be increased when Methantheline is combined with Meperidine. |
| Oxycodone | The risk or severity of adverse effects can be increased when Methantheline is combined with Oxycodone. |
| Butorphanol | The risk or severity of adverse effects can be increased when Methantheline is combined with Butorphanol. |
| Dextropropoxyphene | The risk or severity of adverse effects can be increased when Methantheline is combined with Dextropropoxyphene. |
| Pentazocine | The risk or severity of adverse effects can be increased when Methantheline is combined with Pentazocine. |
| Sufentanil | The risk or severity of adverse effects can be increased when Methantheline is combined with Sufentanil. |
| Alfentanil | The risk or severity of adverse effects can be increased when Methantheline is combined with Alfentanil. |
| Fentanyl | The risk or severity of adverse effects can be increased when Methantheline is combined with Fentanyl. |
| Nalbuphine | The risk or severity of adverse effects can be increased when Methantheline is combined with Nalbuphine. |
| Levorphanol | The risk or severity of adverse effects can be increased when Methantheline is combined with Levorphanol. |
| Remifentanil | The risk or severity of adverse effects can be increased when Methantheline is combined with Remifentanil. |
| Buprenorphine | The risk or severity of adverse effects can be increased when Methantheline is combined with Buprenorphine. |
| Hydrocodone | The risk or severity of adverse effects can be increased when Methantheline is combined with Hydrocodone. |
| Diphenoxylate | The risk or severity of adverse effects can be increased when Methantheline is combined with Diphenoxylate. |
| Oxymorphone | The risk or severity of adverse effects can be increased when Methantheline is combined with Oxymorphone. |
| Dezocine | The risk or severity of adverse effects can be increased when Methantheline is combined with Dezocine. |